Lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
the	the	O	O	O	O
prevention	prevention	O	O	O	O
of	of	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
virus	virus	O	O	O	O
reactivation	reactivation	O	O	O	O
in	in	O	O	O	O
hepatitis-B	hepatitis-b	O	O	O	O
surface	surface	O	O	O	O
antigen	antigen	O	O	O	O
(	(	O	O	O	O
HBSAG	hbsag	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
seropositive	seropositive	O	O	O	O
cancer	cancer	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
undergoing	undergoing	O	O	O	O
cytotoxic	cytotoxic	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
.	.	O	O	O	O

Hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
virus	virus	O	O	O	O
(	(	O	O	O	O
HBV	hbv	O	O	O	O
)	)	O	O	O	O
is	is	O	O	O	O
one	one	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
major	major	O	O	O	O
causes	causes	O	O	O	O
of	of	O	O	O	O
chronic	chronic	O	O	OTHERS	I
liver	liver	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
worldwide	worldwide	O	O	O	O
.	.	O	O	O	O

Cancer	cancer	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
who	who	O	O	O	O
are	are	O	O	O	O
chronic	chronic	O	O	O	O
carriers	carriers	O	O	O	O
of	of	O	O	O	O
HBV	hbv	O	O	O	O
have	have	O	O	O	O
a	a	O	O	O	O
higher	higher	O	O	O	O
hepatic	hepatic	O	O	OTHERS	I
complication	complication	O	O	OTHERS	I
rate	rate	O	O	O	O
while	while	O	O	O	O
receiving	receiving	O	O	O	O
cytotoxic	cytotoxic	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
(	(	O	O	O	O
CT	ct	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
this	this	O	O	O	O
has	has	O	O	O	O
mainly	mainly	O	O	O	O
been	been	O	O	O	O
attributed	attributed	O	O	O	O
to	to	O	O	O	O
HBV	hbv	O	O	O	O
reactivation	reactivation	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
cancer	cancer	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
who	who	O	O	O	O
have	have	O	O	O	O
solid	solid	O	O	O	O
and	and	O	O	O	O
hematological	hematological	O	O	OTHERS	I
malignancies	malignancies	O	DISEASE	OTHERS	I
with	with	O	O	O	O
chronic	chronic	O	O	O	O
HBV	hbv	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
received	received	O	O	O	O
the	the	O	O	O	O
antiviral	antiviral	O	O	O	O
agent	agent	O	O	O	O
lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
prior	prior	O	O	O	O
and	and	O	O	O	O
during	during	O	O	O	O
CT	ct	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
historical	historical	O	O	O	O
control	control	O	O	O	O
group	group	O	O	O	O
who	who	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
receive	receive	O	O	O	O
lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
objectives	objectives	O	O	O	O
were	were	O	O	O	O
to	to	O	O	O	O
assess	assess	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
of	of	O	O	O	O
lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
reducing	reducing	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
HBV	hbv	O	O	O	O
reactivation	reactivation	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
diminishing	diminishing	O	O	O	O
morbidity	morbidity	O	O	O	O
and	and	O	O	O	O
mortality	mortality	O	O	O	O
during	during	O	O	O	O
CT	ct	O	O	O	O
.	.	O	O	O	O

Two	two	O	O	O	O
groups	groups	O	O	O	O
were	were	O	O	O	O
compared	compared	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
prophylactic	prophylactic	O	O	O	O
lamivudin	lamivudin	O	O	OTHERS	I
group	group	O	O	O	O
consisted	consisted	O	O	O	O
of	of	O	O	O	O
37	37	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
received	received	O	O	O	O
prophylactic	prophylactic	O	O	O	O
lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
historical	historical	O	O	O	O
controls	controls	O	O	O	O
consisted	consisted	O	O	O	O
of	of	O	O	O	O
50	50	O	O	O	O
consecutive	consecutive	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
underwent	underwent	O	O	O	O
CT	ct	O	O	O	O
without	without	O	O	O	O
prophylactic	prophylactic	O	O	O	O
lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

They	they	O	O	O	O
were	were	O	O	O	O
followed	followed	O	O	O	O
up	up	O	O	O	O
during	during	O	O	O	O
and	and	O	O	O	O
for	for	O	O	O	O
8	8	O	O	O	O
weeks	weeks	O	O	O	O
after	after	O	O	O	O
CT	ct	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
outcomes	outcomes	O	O	O	O
were	were	O	O	O	O
compared	compared	O	O	O	O
for	for	O	O	O	O
both	both	O	O	O	O
groups	groups	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
our	our	O	O	O	O
control	control	O	O	O	O
group	group	O	O	O	O
(	(	O	O	O	O
n=	n=	O	O	O	O
50	50	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
21	21	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
42	42	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
established	established	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Twelve	twelve	O	O	O	O
(	(	O	O	O	O
24	24	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
them	them	O	O	O	O
were	were	O	O	O	O
evaluated	evaluated	O	O	O	O
as	as	O	O	O	O
severe	severe	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
prophylactic	prophylactic	O	O	O	O
lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
group	group	O	O	O	O
severe	severe	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
were	were	O	O	O	O
observed	observed	O	O	O	O
only	only	O	O	O	O
in	in	O	O	O	O
1	1	O	O	O	O
patient	patient	O	O	O	O
(	(	O	O	O	O
2.7	2.7	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
37	37	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
0.006	0.006	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Comparison	comparison	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
mean	mean	O	O	O	O
ALT	alt	O	O	O	O
values	values	O	O	O	O
revealed	revealed	O	O	O	O
significantly	significantly	O	O	O	O
higher	higher	O	O	O	O
mean	mean	O	O	O	O
alanine	alanine	CHEMICALS	O	OTHERS	I
aminotransferase	aminotransferase	O	O	O	O
(	(	O	O	O	O
ALT	alt	O	O	O	O
)	)	O	O	O	O
values	values	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
control	control	O	O	O	O
group	group	O	O	O	O
than	than	O	O	O	O
the	the	O	O	O	O
prophylactic	prophylactic	O	O	O	O
lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
group	group	O	O	O	O
;	;	O	O	O	O
154:64	154:64	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
0.32	0.32	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Our	our	O	O	O	O
study	study	O	O	O	O
suggests	suggests	O	O	O	O
that	that	O	O	O	O
prophylactic	prophylactic	O	O	O	O
lamivudine	lamivudine	CHEMICALS	O	OTHERS	I
significantly	significantly	O	O	O	O
decreases	decreases	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
HBV	hbv	O	O	O	O
reactivation	reactivation	O	O	O	O
and	and	O	O	O	O
overall	overall	O	O	O	O
morbidity	morbidity	O	O	O	O
in	in	O	O	O	O
cancer	cancer	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
during	during	O	O	O	O
and	and	O	O	O	O
after	after	O	O	O	O
immunosuppressive	immunosuppressive	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

Further	further	O	O	O	O
studies	studies	O	O	O	O
are	are	O	O	O	O
needed	needed	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
most	most	O	O	O	O
appropriate	appropriate	O	O	O	O
nucleoside	nucleoside	O	O	OTHERS	I
or	or	O	O	O	O
nucleotide	nucleotide	O	O	OTHERS	I
analogue	analogue	O	O	O	O
for	for	O	O	O	O
antiviral	antiviral	O	O	O	O
prophylaxis	prophylaxis	O	O	O	O
during	during	O	O	O	O
CT	ct	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
optimal	optimal	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
administration	administration	O	O	O	O
after	after	O	O	O	O
completion	completion	O	O	O	O
of	of	O	O	O	O
CT	ct	O	O	O	O
.	.	O	O	O	O

